ALGN at a glance
Align Technology (ALGN, SEC CIK 1097149) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 31, 2026 and Form 4 insider filings as recently as August 31, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Align Technology (ALGN) reported revenue of $4.0 billion (up 0.9% from FY2024) and net income of $410.4 million. Diluted EPS was $5.65.
- As of June 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Align Technology (ALGN) shares worth $5.2 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.0B
- +0.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 38 funds
- $5.2B · +1 vs prior quarter
- Latest 8-K
- Aug 31, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Section 232 investigation by U.S. Dept of Commerce into PPE/medical device imports directly threatens Align's Mexico-manufactured clear aligners shipped to U.S.
- iTero HQ in Israel near Hamas conflict zone; Mexico manufacturing exposed to drug cartel/gang activity disrupting production and logistics
- Heavy dependence on sole-source suppliers for specialized resin, rapid prototyping machines, and iTero optics components with no quick replacement path
- Competitors integrating AI/ML into orthodontic workflows risk commoditizing Invisalign; DTC aligner companies bypassing doctor channel further erode pricing power
- Revenue concentrated in Invisalign System as primary revenue driver; restructuring plans executed three consecutive fiscal years signal persistent operational instability
Management Discussion & Analysis
- Revenue $4,035M, up 0.9% YoY ($+$36M); Clear Aligner +0.5% to $3,245M, Systems & Services +2.7% to $790M
- Gross margin 67.2% vs 70.0%; operating margin 13.5% vs 15.2%; Clear Aligner margin 31.9% vs 35.4%; Systems & Services margin 38.8% vs 35.0%
- Best segment: Systems & Services op margin 38.8% vs 35.0%; worst: Clear Aligner dragged by $77M accelerated depreciation and ASP decline 3.9% ($1,245 vs $1,295)
- Operating cash flow $593M vs $738M YoY; capex $102M; buybacks $466M; $831M remaining under repurchase program; no dividends
- Key risks: tariff volatility, macro uncertainty dampening discretionary spending, orthodontic starts down four consecutive years; FY2026 capex guided $125–$150M
Business Overview
- Global med-device co: design/manufacture/market Invisalign clear aligners (~80% revenue), iTero scanners, and exocad CAD/CAM software via integrated Align Digital Platform
- 2025 new launches: iTero Lumina Pro with NIRI technology (March), Align X-ray Insights AI-based caries detection in EU/UK (March), Invisalign MAOB for Class II teen patients (December)
- Direct fabrication via Cubicure (acquired Jan 2024) scaling toward millions of 3D-printed devices/day; retainers and pre-fab attachments pilot releases planned 2026
- Headcount ~20,290 as of Dec 31, 2025: down 3.1% YoY and 6.1% vs 2023, signaling ongoing workforce contraction despite product expansion
- Invisalign holds only ~10% share of ~22M annual global orthodontic case starts: massive untapped market framing core growth narrative
AI summary of the ALGN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $1,056.2M, up 4.3% YoY from $1,012.4M
- Operating margin 14.6% vs 16.1% YoY; gross margin 71.7% vs 69.9%
- Best segment Clear Aligner revenue $870.9M, up 8.2%; operating margin 37.4% vs 33.2%
- Worst segment Systems and Services revenue $185.3M, down 10.8%; operating margin 41.9% vs 41.3%
- Cash $1,103M; operating cash flow $193M; capital expenditures $36M
- Headwinds: tariffs, geopolitical tensions, consumer uncertainty, lower orthodontic starts, and $37.5M UK VAT contingency
Risk Factors
- New Section 301 duties imposed July 24, 2026 on imports from the top 60 U.S. trade partners, potentially indefinitely
- Regulatory risk from uncertain tariff rates, scope, duration, and pending litigation outcomes
- Middle East hostilities affecting Israel-based iTero operations, oil shipments, logistics, and energy prices
- Competition from AI-enabled orthodontic and scanner products threatening technology relevance and pricing
- Foreign-currency exposure from significant international revenues and expenses despite forward-contract hedging
AI summary of the ALGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Quentin Blackford appointed director effective immediately, adding global healthcare, medical technology, and digital innovation expertise
- Board expanded to 11 directors, then returns to 10 after Andrea Saia’s September 23, 2026 retirement
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Quentin Blackford, 48, appointed director effective August 27, 2026
- Board temporarily expands from 10 to 11 directors before Andrea Saia’s September 23, 2026 resignation
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, released July 29, 2026
- Conference call scheduled to discuss quarterly financial performance
Item 7.01: Regulation FD Disclosure
- Align announced strategic initiatives targeting long-term growth and shareholder value creation
- Full strategic details are in Exhibit 99.1, making that release essential for assessing financial and operational implications
Item EX-99.1: Item EX-99.1
- Three new independent directors planned, intensifying governance refreshment following discussions with Elliott Investment Management
- Strategic operating-model review targets commercial execution, organizational efficiency, scalability, margin expansion, and earnings growth
AI summaries of ALGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALGN
Don't miss the next ALGN filing
- Alerts as it files. A push when ALGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALGN, by share count.
- Ask anything. An AI agent that reads every ALGN filing and answers with sources.
ALGN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Blackford Quentin S. | A | Aug 27, 2026 | 1,376 | - |
| Conroy Kevin T | M | May 20, 2026 | 1,745 | - |
| Vitalone Britt J. | M | May 20, 2026 | 1,443 | - |
| LACOB JOSEPH | M | May 20, 2026 | 1,745 | - |
| LACOB JOSEPH | M | May 20, 2026 | 1,745 | - |
| LACOB JOSEPH | A | May 20, 2026 | 1,836 | - |
| Saia Andrea Lynn | M | May 20, 2026 | 1,745 | - |
| Vitalone Britt J. | M | May 20, 2026 | 1,443 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.0B | $4.0B |
| Gross Profit | - | $2.8B | $2.7B |
| Operating Income | - | $607.6M | $545.8M |
| Net Income | - | $421.4M | $410.4M |
| Gross Margin | - | 70.0% | 67.2% |
| Op. Margin | - | 15.2% | 13.5% |
| Net Margin | - | 10.5% | 10.2% |
| Balance Sheet | |||
| Total Assets | $6.1B | $6.2B | $6.2B |
| Equity | - | $3.9B | $4.0B |
| ROE | - | 10.9% | 10.1% |
| Per Share | |||
| EPS | - | $5.62 | $5.65 |
| Cash Flow | |||
| Operating CF | - | $738.2M | $593.2M |
| CapEx | $177.7M | $115.6M | $102.4M |
Source: XBRL data in Align Technology (ALGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ALGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 38 | $5.16B |
| Q1 2026 | 37 | $4.66B |
| Q4 2025 | 35 | $4.23B |
| Q3 2025 | 37 | $3.53B |
| Q2 2025 | 35 | $5.33B |
| Q1 2025 | 31 | $3.62B |
| Q4 2024 | 28 | $4.16B |
| Q3 2024 | 25 | $2.50B |
- Goldman Sachs Group+1.58M (+88%)
- FMR LLC (Fidelity)+1.36M (+50%)
- Dimensional Fund Advisors+466.4K (+48%)
- D.E. Shaw & Co+143.8K (+214%)
- BlackRock+129.4K (+3%)
- Citadel Advisors LLC−430.9K (-59%)
- Millennium Management−90.5K (-79%)
- BNY Mellon−61.2K (-15%)
- Wells Fargo & Co−47.9K (-15%)
- Raymond James Financial−45.0K (-22%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 266 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 4 | Aug 31, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 8-K | May 20, 2026 | - | Analysis | |
| SC 13G | May 14, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 1, 2026 | - | Analysis | - |
| 8-K | Apr 29, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 10-K | Feb 27, 2026 | Dec 31, 2025 | Analysis |
Related Health Care companies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
- MYO · MYOMO, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
ALGN SEC filings: frequently asked questions
Which institutions hold ALGN stock?
As of June 30, 2026, the largest Align Technology (ALGN) holders among the 13F filers tracked by SignalX were BlackRock ($745.4 million), Vanguard Capital Management LLC ($742.3 million), FMR LLC (Fidelity) ($684.8 million), Goldman Sachs Group ($568.8 million), Vanguard Portfolio Management LLC ($528.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ALGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Align Technology (ALGN) reported revenue of $4.0 billion (up 0.9% from FY2024) and net income of $410.4 million. Diluted EPS was $5.65. The figures come from the XBRL data in the 10-K.
What are the main risks in ALGN's latest 10-K?
In the 10-K filed February 27, 2026, Align Technology (ALGN) flagged: Section 232 investigation by U.S. Dept of Commerce into PPE/medical device imports directly threatens Align's Mexico-manufactured clear aligners shipped to U.S. iTero HQ in Israel near Hamas conflict zone; Mexico manufacturing exposed to drug cartel/gang activity disrupting production and logistics. (AI summary of the Risk Factors section.)
What did ALGN report in its latest 8-K?
Align Technology (ALGN) filed an 8-K on August 31, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Quentin Blackford appointed director effective immediately, adding global healthcare, medical technology, and digital innovation expertise.
What are the latest ALGN SEC filings?
Align Technology (ALGN) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 31, 2026 and a Form 4 insider filing on August 31, 2026.
What is ALGN's SEC CIK number?
Align Technology (ALGN)'s SEC Central Index Key (CIK) is 1097149. EDGAR lists every ALGN filing under that number.
Ask anything about ALGN
The research agent reads ALGN's filings, financials, insider trades and 13F holders, then answers with sources.